Table 1 The efficacy of sabatolimab in the treatment of AML and MDS
From: Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting
Clinical trial identifier | NCT03066648 | NCT03946670 | |||||||
|---|---|---|---|---|---|---|---|---|---|
Phase | Ib | IIb | |||||||
Interventions | MBG453 + HMA | MBG453 + HMA | Placebo + HMA | ||||||
Cancer type (population, N) | vHR/HR-MDS(N = 51) | MDS with TP53 | ND-AML(N = 40) | AML with TP53/RUNX1/ASXL1 | IR/HR/vHR-MDS (N = 65) | MDS (BM blasts < 10%,N = 32) | IR/HR/vHR-MDS (N = 62) | MDS (BM blasts < 10%, N = 29) | |
mDOR of CR (month) | 21.5 | 23 | 18.0 | 9.2 | |||||
ORR rate (%) | 56.9 | 71.4 | 40 | 53.8 | / | ||||
mDOR (month) | 16.1 | 21.5 | 12.6 | 12.6 | / | ||||
1 year PFS (%) | 51.9 | 27.9 | / | ||||||
mPFS (month) | / | 11.1 | 11.3 | 8.5 | 8.3 | ||||
CR rate (%) | / | 23.1 | 28.1 | 21.0 | 17.2 | ||||
CR + PR + HI rate (%) | / | 49.2 | 53.1 | 37.1 | 34.5 | ||||
M (CR + PR + HI) (month) | / | 13.4 | 9.2 | ||||||
OS (month) | / | 19.0 | 18.0 | ||||||